Equities research analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will report ($0.78) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.91) to ($0.64). Heron Therapeutics reported earnings per share of ($1.03) during the same quarter last year, which suggests a positive year over year growth rate of 24.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($3.37) per share for the current year, with EPS estimates ranging from ($3.42) to ($3.30). For the next year, analysts anticipate that the firm will report earnings of ($2.22) per share, with EPS estimates ranging from ($2.93) to ($1.52). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Heron Therapeutics.
HRTX has been the subject of a number of recent analyst reports. Mizuho restated a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cowen restated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Monday, November 6th. Cantor Fitzgerald restated a “buy” rating and set a $31.00 price objective on shares of Heron Therapeutics in a report on Thursday, November 2nd. Oppenheimer initiated coverage on Heron Therapeutics in a report on Monday, October 30th. They set a “buy” rating and a $27.00 price objective for the company. Finally, Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Wednesday, November 22nd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Heron Therapeutics presently has a consensus rating of “Buy” and an average target price of $29.92.
Heron Therapeutics (HRTX) traded up $0.10 on Wednesday, reaching $22.60. The company had a trading volume of 864,562 shares, compared to its average volume of 975,857. Heron Therapeutics has a one year low of $12.70 and a one year high of $24.80. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. The stock has a market cap of $1,230.00, a PE ratio of -5.96 and a beta of 1.87.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of Heron Therapeutics stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total transaction of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at approximately $151,680. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 19.93% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. C WorldWide Group Holding A S bought a new stake in Heron Therapeutics during the 3rd quarter valued at $1,615,000. Alyeska Investment Group L.P. raised its position in Heron Therapeutics by 9.5% during the 3rd quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock valued at $12,188,000 after purchasing an additional 65,260 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Heron Therapeutics by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 8,135 shares in the last quarter. Asymmetry Capital Management L.P. bought a new position in shares of Heron Therapeutics in the 3rd quarter worth $1,017,000. Finally, Deltec Asset Management LLC bought a new position in shares of Heron Therapeutics in the 4th quarter worth $2,118,000.
COPYRIGHT VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/21/brokerages-anticipate-heron-therapeutics-inc-hrtx-will-announce-earnings-of-0-78-per-share.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.